Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion

Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):782-3. doi: 10.1007/s00417-002-0529-0. Epub 2002 Aug 13.

Abstract

Purpose: To report the clinical outcome of a patient receiving an intravitreal injection of triamcinolone acetonide as treatment of bilateral, long-standing, cystoid macular edema due to central retinal vein occlusion.

Methods: A 70-years-old patient suffering from bilateral central retinal vein occlusion for 2 years and 1.5 years, respectively, received transconjunctivally an intravitreal injection of 25 mg of crystalline triamcinolone acetonide in each eye, with 10 weeks between injections.

Results: During the follow-up period of 4 months (OD) and 6 weeks (OS), respectively, visual acuity increased from 0.05 to 0.25 in his right eye and from 0.125 to 0.25 in his left eye. Fluorescein angiography showed a decrease of fluorescein leakage in the macular area.

Conclusions: Intravitreal injection of triamcinolone acetonide may be a therapeutic option for long-standing cystoid macular edema due to central retinal vein occlusion.

MeSH terms

  • Aged
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Male
  • Retinal Vein Occlusion / complications*
  • Triamcinolone Acetonide / therapeutic use*
  • Visual Acuity
  • Vitreous Body

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide